Andrea Stefek

1.9k total citations
14 papers, 193 citations indexed

About

Andrea Stefek is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrea Stefek has authored 14 papers receiving a total of 193 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 9 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrea Stefek's work include Breast Cancer Treatment Studies (11 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (5 papers). Andrea Stefek is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (5 papers). Andrea Stefek collaborates with scholars based in Germany, United States and Austria. Andrea Stefek's co-authors include Toralf Reimer, Christoph Uleer, Rachel Wuerstlein, Hans Kreipe, Ulrike Nitz, Nadia Harbeck, Cornelia Liedtke, Ronald Kates, Matthias Christgen and Oleg Gluz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Andrea Stefek

13 papers receiving 192 citations

Peers

Andrea Stefek

ONCOL

PRM

PFM

GENET

Arun Nagarajan United States

Piergiorgio Giannessi Italy

Elena Aguirre Spain

Hannah Maynard United States

Angels Arcusa Lanza Spain

Jane Banerji United Kingdom

Tetsuhiro Yoshinami Japan

David Riseberg United States

CE Geyer United States

Ignacio Tusquets Spain

Arun Nagarajan United States

Andrea Stefek

161 ×1.1

ONCOL

89 ×0.6

46 ×0.9

PRM

39 ×1.1

PFM

24 ×0.8

GENET

Citations per year, relative to Andrea Stefek Andrea Stefek (= 1×) peers Arun Nagarajan

Countries citing papers authored by Andrea Stefek

Since Specialization

Citations

This map shows the geographic impact of Andrea Stefek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Stefek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Stefek more than expected).

Fields of papers citing papers by Andrea Stefek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Stefek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Stefek. The network helps show where Andrea Stefek may publish in the future.

Co-authorship network of co-authors of Andrea Stefek

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Stefek. A scholar is included among the top collaborators of Andrea Stefek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Stefek. Andrea Stefek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Reimer, Toralf, Angrit Stachs, Silke Polata, et al.. (2022). Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): a randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 55. 101756–101756. 39 indexed citations

Gerber, Bernd, Angrit Stachs, Silke Polata, et al.. (2022). Abstract GS4-03: Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer. Cancer Research. 82(4_Supplement). GS4–3. 4 indexed citations

Schmid, Peter, Duncan Wheatley, Pankaj G. Roy, et al.. (2021). 208P ARB: Phase II window of opportunity study of preoperative treatment with enzalutamide in ER+ve and TNBC. Annals of Oncology. 32. S449–S450. 1 indexed citations

Harbeck, Nadia, Oleg Gluz, Matthias Christgen, et al.. (2021). De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.. Journal of Clinical Oncology. 39(15_suppl). 503–503. 11 indexed citations

Hauke, Jan, Corinna Ernst, Peter A. Fasching, et al.. (2020). 176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Annals of Oncology. 31. S313–S313. 3 indexed citations

Wuerstlein, Rachel, Nadia Harbeck, Eva‐Maria Grischke, et al.. (2020). Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. Breast Care. 16(1). 50–58.

Christgen, Matthias, Nadia Harbeck, Oleg Gluz, et al.. (2020). Differential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trial. European Journal of Cancer. 138. S1–S1. 1 indexed citations

Nitz, Ulrike, Oleg Gluz, Michael Clemens, et al.. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. Journal of Clinical Oncology. 37(10). 799–808. 74 indexed citations

Fasching, Peter A., Christian Jackisch, Kerstin Rhiem, et al.. (2019). GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).. Journal of Clinical Oncology. 37(15_suppl). 506–506. 34 indexed citations

10.

Gluz, Oleg, Rachel Wuerstlein, Michael Clemens, et al.. (2018). Abstract P1-06-06: No age-related outcome disparities according to 21-gene recurrence score groups in early breast cancer patients treated by adjuvant chemotherapy in the prospective WSG PlanB trial. Cancer Research. 78(4_Supplement). P1–6. 1 indexed citations

11.

Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2017). Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results. Annals of Oncology. 28. v606–v606. 1 indexed citations

12.

Harbeck, Nadia, Oleg Gluz, Michael Clemens, et al.. (2017). Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 504–504. 8 indexed citations

13.

Nitz, Ulrike, Oleg Gluz, Matthias Christgen, et al.. (2016). Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).. Journal of Clinical Oncology. 34(15_suppl). 518–518. 8 indexed citations

14.

Gluz, Oleg, Ulrike Nitz, Matthias Christgen, et al.. (2016). Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.. Journal of Clinical Oncology. 34(15_suppl). 556–556. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact